Ostenil Injections with Ostenil® Plus is a treatment for the symptoms of Osteoarthritis. It can be used in the knee, or in any other joints in the body that are classified as ‘synovial joint’. These are clinically proven to reduce the pain associated with Osteoarthritis
OSTENIL® TENDON was developed to treat painful tendinopathy. It also helps to restore restricted mobility in tendon disorders caused, for example, by overuse or inappropriate biomechanical stress. It is highly concentrated sodium hyaluronate (2%).
Ostenil® Plus is a solution containing sodium hyaluronate. It is injected into the space in the joint that contains synovial fluid and works by restoring the normal balance between the breakdown and production of sodium hyaluronate. This procedure is known as ‘viscosupplementation’, and the effect of Ostenil® Plus means that it can decrease pain and stiffness and improve the other symptoms of osteoarthritis.
The sodium hyaluronate in Ostenil® Plus is very pure and is manufactured using a process called fermentation. It contains no animal proteins, which means that it is very unlikely to cause an allergic reaction. Ostenil® Plus has been given to thousands of patients and has not been found to cause any serious side effects. The exact make-up of the sodium hyaluronate in Ostenil® Plus has been carefully chosen so that it is as effective as possible in treating osteoarthritis.
OSTENIL® TENDON was developed to treat pain and restricted mobility in tendon disorders caused, for example, by overuse or inappropriate biomechanical stress. It is highly concentrated sodium hyaluronate (2%).
The lubricating characteristics of sodium hyaluronate increase tendon gliding and reduce agglutinations (stickiness). The tendon can work again as if well-oiled. Furthermore, sodium hyaluronate blocks pain receptors, hinders inflammatory mediators, and is a good transport medium for nutrients.
OSTENIL® TENDON ensures a harmonisation of the tendons and the surrounding structures, reduces pain and increases joint function.
The treatment itself takes very little time. Your doctor will give you an injection into the area around the most damaged part of the affected tendon, usually employing some form of visual guidance equipment such as Ultra-Sound, which helps ensure the injection is placed correctly. In the case of tendons within a tendon sheath, Your Therapist will inject OSTENIL® TENDON into the tendon sheath itself. In either case, the lubricant will be distributed through natural movement along the entire tendon. A repeat injection, normally given a week after the first, may be required in more established and persistent tendon disease.
In studies done in Germany the treatment scheme described above has proved to be effective and safe. In most cases, there is a quick and long-lasting improvement of joint function. Several tendons may be treated at the same time. If symptoms return the treatment can be repeated.
What you should know about private medical insurers?
Private medical insurers may sometimes give the impression that they will not reimburse OSTENIL® or OSTENIL® PLUS injections, and, as a result, you may be led to offer OSTENIL® injections only for self-funding patients.
However, the fact is that Bupa, Aviva, AXA-PPP and VitalityHealth will fund viscosupplementation if you use the correct specific code that the insurers require. Please have a look at this website: www.ccsd.org.uk. The “Clinical Coding & Schedule Development Group” provides the specific codes used by the four major insurers (BUPA, Aviva, AXA-PPP, and VitalityHealth) for injecting a viscosupplement into a joint with or without guidance.
The relevant codes for AXA-PPP, Aviva and VitalityHealth can be found by clicking the ‘procedural’ (green) tab and entering ‘Viscosupplement’ in the search box. The codes that come up are:
W9032 – Injection of viscosupplement into joint WITH image guidance
W9033 – Injections of viscosupplement into joints WITH image guidance (bilateral)
W9042 – Injection of viscosupplement into joint
W9043 – Injections of viscosupplement into joints (bilateral)
The code for BUPA for Ostenil Injections is AA663, which has to be used in conjunction with W9030 (joint injection under guidance), or W9040 (joint injection without guidance). If you go to the individual insurers websites then you can also see how much they pay for using each of the codes and what restrictions there are.
Sometimes an insurer may say that they will only cover the cost of a visco supplement injected into the knee and not any other joint. However, on the codes schedule it does not specify that the related codes are only for the knee. This means injections into other joints, i.e. hip, shoulder, ankle, etc, should also be covered by the insurers. However, the insurers will have their own specific policy regarding applicable clinical circumstances and products to be used.
A: Yes, if you:
A: These are very rare and your clinician will discuss them with you:
A: Not particularly, as your therapist has had intensive training in the technique. Sometimes it can be sore for a few hours, but you will be told what to do about this.
A: If local anaesthetic is also used the pain should be less within a few minutes, though it may return after about an hour. The steroid usually starts to work within 24-48 hours but may take longer.
A: This varies from person to person and the condition being treated, but the steroid usually continues working for 3 to 6 weeks.
A: This depends on the part of the body involved and will be decided by your therapist and yourself. Usually one injection is sufficient, but if the pain is severe or has been there for a long time, you may need more.
A: If the problem was caused by overuse, you will probably be told to rest the area for about a week; if it is a joint pain, you may start early gentle movement.
A: Here at Core Physio, your therapist will want to see you again about a week or ten days after the ostenil injections. You will then be given appropriate physiotherapy treatment and probably some exercises for you to do at home. You will also usually be reviewed a month after the injection to monitor the long term effect of the treatment.